Author

Matina Lydia Chatzinikolaou

PRELIMINARY DATA ON THE EFFICACY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS IN A 'REAL-WORLD' CLINICAL SETTING
PRELIMINARY DATA ON THE EFFICACY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS IN A 'REAL-WORLD' CLINICAL SETTING

Matina Lydia Chatzinikolaou  et al.

MANAGEMENT AND OUTCOME OF CYTOMEGALOVIRUS INFECTION IN ULCERATIVE COLITIS PATIENTS
MANAGEMENT AND OUTCOME OF CYTOMEGALOVIRUS INFECTION IN ULCERATIVE COLITIS PATIENTS

Matina Lydia Chatzinikolaou  et al.

THE VEDOLIZUMAB CLINICAL DECISION SUPPORT TOOL FOR CROHN'S DISEASE EFFECTIVELY PREDICTS CLINICAL REMISSION AT 54 WEEKS IN A "REAL WORLD" SETTING
THE VEDOLIZUMAB CLINICAL DECISION SUPPORT TOOL FOR CROHN'S DISEASE EFFECTIVELY PREDICTS CLINICAL REMISSION AT 54 WEEKS IN A "REAL WORLD" SETTING

Matina Lydia Chatzinikolaou  et al.

LONG TERM PERSISTENCE OF USTEKINUMAB IN CROHN’S DISEASE: CLINICAL OUTCOMES AND PROGNOSTIC FACTORS
LONG TERM PERSISTENCE OF USTEKINUMAB IN CROHN’S DISEASE: CLINICAL OUTCOMES AND PROGNOSTIC FACTORS

Matina Lydia Chatzinikolaou  et al.

Item 1 - 4 / 4
1